Co-Diagnostics, Inc. (CODX)

Market Cap	19.45M
Revenue (ttm)	1.00M
Net Income (ttm)	-35.99M
Shares Out	48.14M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,608,690
Open	0.4502
Previous Close	0.4600
Day's Range	0.3950 - 0.4600
52-Week Range	0.2275 - 1.5500
Beta	1.14
Analysts	Buy
Price Target	2.00 (+394.93%)
Earnings Date	Nov 13, 2025

About CODX

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 12, 2017
• Employees: 132
• Stock Exchange: NASDAQ
• Ticker Symbol: CODX
• Website: https://co-dx.com

Financial Performance

In 2024, Co-Diagnostics's revenue was $3.92 million, a decrease of -42.53% compared to the previous year's $6.81 million. Losses were -$37.64 million, 6.53% more than in 2023.

Analyst Summary

According to 2 analysts, the average rating for CODX stock is "Buy." The 12-month stock price target is $2.0, which is an increase of 394.93% from the latest price.

Price Target

$2.0

(394.93% upside)

Analyst Consensus: Buy